Spiriva HandiHaler

DRUG4 trials

Sponsors

Boehringer Ingelheim, GlaxoSmithKline, Wake Forest University Health Sciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

COPDCOPD ExacerbationChronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 1

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Active, not recruitingNCT06326671

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease

Start: 2024-02-28End: 2024-04-30Updated: 2024-03-29

Phase 4

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

CompletedNCT01644734

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2011-11-30End: 2013-03-31Updated: 2014-05-26

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

TerminatedNCT03219866

Wake Forest University Health SciencesCOPD, COPD Exacerbation

Start: 2017-10-03End: 2020-04-01Updated: 2021-06-22

Unknown Phase

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

CompletedNCT03114969

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2017-06-08End: 2018-03-09Updated: 2020-10-28